Forecast

Buy	6
Hold	2
Sell	0

News Go to news feed

Lifeward shareholders approve partnership with Oramed and potential capital injection

Lifeward has approved the issuance of common shares as part of a strategic partnership with Oramed, potentially giving the company access to up to about $47 million from Oramed and an additional investor. The financing includes equity, convertible bonds, milestone payments and warrants. Oramed will manage and fund the clinical development program for the POD technology, which aims to enable oral delivery of biopharmaceuticals, while Lifeward will focus on its medical technology business. Lifeward shares jumped more than 10% after the announcement but remain down around 65% year-to-date; completion of the transaction is still subject to customary conditions. » More on de.investing.com
Oramed receives $18 million from Scilex and announces cash dividend

Oramed has received a payment of $18 million from Scilex, fulfilling all obligations under an option agreement and raising the total return on the original $99.5 million investment to $118 million. Oramed also retains a $27 million promissory note, a $12 million convertible note (conversion price $36 per share), warrants and a nine‑year royalty/license interest in Scilex products. The board approved a cash dividend of $0.25 per share (ex‑date January 16, 2026; payment January 26, 2026), to be financed from surplus funds; the share price then rose by about 6.2%. » More on de.investing.com
Oramed Pharmaceuticals: Leonard Sank steps down from director post after 18 years

Leonard Sank has announced he will resign his mandate on the supervisory board of Oramed Pharmaceuticals effective January 1, 2026. The company emphasizes that his resignation is not due to disagreements over management, policies, or practices. Sank served 18 years as a director. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Oramed Pharmaceuticals has already paid 0,21€ in dividends. The last payout was in January.

Financials

In the last quarter, Oramed Pharmaceuticals had revenue of 0.00€ and net profit of 68.48m€

(EUR)	Jun 2026	YoY
Revenue	0.00	-
Gross profit	0.00	-
Net profit	+68.48m	507,43%
EBITDA	+89.01m	696,98%

Fundamentals

Metric	Value
Market capitalization	+182.98m€
Number of shares	40.93m
52-week high/low	+4,51€ - +1,79€
Dividend yield	+4,57%
Dividends TTM	+0,21€
Beta	1,16
P/E ratio	+1,23
PEG ratio	0,00
P/B ratio	+0,67
P/S ratio	0,00

Company profile

Oramed Pharmaceuticals Inc. beschäftigt sich mit der Erforschung und Entwicklung von pharmazeutischen Lösungen für die Behandlung von Diabetes und für die Verwendung von oral einnehmbaren Kapseln oder Pillen zur Verabreichung von Polypeptiden. Das firmeneigene Vorzeigeprodukt ist ORMD-0801, eine oral einnehmbare Insulinkapsel, die klinische Studien der Phase II zur Behandlung von Diabetikern abgeschlossen hat. Darüber hinaus entwickelt das Unternehmen ORMD-0901, eine oral einzunehmende Glucagon-like Peptide-1-Kapsel, die die klinischen Studien der Phase I zur Behandlung von Typ-2-Diabetes abgeschlossen hat, sowie eine oral einzunehmende Leptin-Kapsel zur Gewichtsreduktion. Das Unternehmen war früher unter dem Namen Integrated Security Technologies, Inc. bekannt und änderte im April 2006 seinen Namen in Oramed Pharmaceuticals Inc. Oramed Pharmaceuticals Inc. wurde im Jahr 2002 gegründet und hat seinen Sitz in New York, New York.